Brokerages Set Haemonetics Corporation (NYSE:HAE) Price Target at $79.70

Haemonetics Corporation (NYSE:HAE) has received an average recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $79.70.

Several research firms have commented on HAE. BTIG Research reiterated a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research note on Friday, November 21st. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Haemonetics in a research report on Monday, December 1st. Barrington Research raised their price objective on Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research note on Friday, November 14th.

Haemonetics Stock Performance

NYSE:HAE opened at $83.18 on Friday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. The stock has a market capitalization of $3.89 billion, a PE ratio of 24.32, a P/E/G ratio of 1.51 and a beta of 0.29. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $85.23. The company has a fifty day moving average of $62.53 and a two-hundred day moving average of $63.90.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The business had revenue of $327.32 million for the quarter, compared to analyst estimates of $311.61 million. During the same quarter last year, the business earned $1.12 earnings per share. The company’s revenue for the quarter was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, research analysts forecast that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Institutional investors and hedge funds have recently bought and sold shares of the business. EverSource Wealth Advisors LLC raised its holdings in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 165 shares during the last quarter. Quarry LP grew its position in shares of Haemonetics by 63.4% in the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 192 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Haemonetics by 91.7% in the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 320 shares during the last quarter. Finally, Versant Capital Management Inc lifted its position in Haemonetics by 216.4% during the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 567 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.